The pair continued to carry out exploratory research ... Its in-house pipeline is headed by MORF-057, an orally-available alpha 4 beta 7 integrin inhibitor that is currently in phase 2 testing ...
The detailed sequence of events following ECM binding to the integrin is not known, but the β-subunit cytoplasmic domain interacts directly with talin, and talin interacts with both vinculin and ...
The deal is expected to close sometime in the third quarter. MORF-057 is an α4β7 integrin inhibitor currently in a pair of phase 2 trials in ulcerative colitis and a third in Crohn’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback